TGF-β1 inhibition reduces cell invasiveness, possibly via partial EMT reversion in vitro, and reduction of both TGF-β1, and AFP plasma levels have been shown to be associated with effective therapy in HCC patients [17, 21]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.